Organovo Holdings, Inc. To Present At Regen Med Investor Day March 26 In New York
 | More News by Company: |  |
 |  |
| Press Release: | |
| Mar 24, 2014 — SAN DIEGO, -- Organovo Holdings, Inc. (NYSE MKT: ONVO) ("Organovo"), a three-dimensional biology company focused on delivering breakthrough 3D bioprinting technology, announced today that Barry Michaels, Chief Financial Officer, will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. Organized by the Alliance for Regenerative Medicine (ARM) in partnership with leading financial firms Maxim Group and Piper Jaffray, this one-day investor conference focuses exclusively on the regenerative medicine and advanced therapies sector. The event includes clinical and commercial experts who will be on-hand to address specific questions regarding the outlook for the industry, as well as offer insight into how regenerative medicine products could impact the standard of care in key therapeutic areas. The program will include talks by key opinion leaders in the industry, life science investment experts and analysts as well as presentations by more than 30 leading companies from across the globe. The following are specific details regarding Organovo's presentation: Event Date: March 26, 2014 Presentation Time: 4:45 – 5:00 p.m. Location: West Lounge Room, Metropolitan Club, One East 60th Street, New York, NY 10022 Attendance at this event is for credentialed investors and members of the media only. If you are interested in attending, please contact Laura Parsons at lparsons@alliancerm.org. Please visit Arminvestorday.com (link below) for more information. About Organovo Holdings, Inc. Organovo designs and creates functional, three-dimensional human tissues for medical research and therapeutic applications. The Company is collaborating with pharmaceutical and academic partners to develop human biological disease models in three dimensions. These 3D human tissues have the potential to accelerate the drug discovery process, enabling treatments to be developed faster and at lower cost. In addition to numerous scientific publications, the Company's technology has been featured in The Wall Street Journal, Time Magazine, The Economist, and numerous others. Organovo is changing the shape of medical research and practice. Learn more at Organovo.com. About the Alliance for Regenerative Medicine The Alliance for Regenerative Medicine (ARM) is a Washington, DC-based multi-stakeholder advocacy organization that promotes legislative, regulatory and reimbursement initiatives necessary to facilitate access to life-giving advances in regenerative medicine and advanced therapies. ARM also works to increase public understanding of the field and its potential to transform human healthcare, providing business development and investor outreach services to support the growth of its member companies and research organizations. Prior to the formation of ARM in 2009, there was no advocacy organization operating in Washington, DC to specifically represent the interests of the companies, research institutions, investors and patient groups that comprise the entire regenerative medicine community. Today ARM has more than 150 members and is the leading global advocacy organization in this field. To learn more about ARM or to become a member, visit Alliancerm.org. Safe Harbor Statement Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Any forward-looking statements contained herein are based on current expectations, but are subject to a number of risks and uncertainties. The factors that could cause actual future results to differ materially from current expectations include, but are not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; and the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies. These and other factors are identified and described in more detail in our filings with the SEC, including our prospectus supplement filed with the SEC on November 27, 2013 and our transition report on Form 10-KT filed with the SEC on May 24, 2013 as well as our other filings with the Securities and Exchange Commission. You should not place undue reliance on these forward-looking statements, which speak only as of the date that they were made. These cautionary statements should be considered with any written or oral forward-looking statements that we may issue in the future. Except as required by applicable law, including the securities laws of the United States, we do not intend to update any of the forward-looking statements to conform these statements to reflect actual results, later events or circumstances or to reflect the occurrence of unanticipated events. | ||
| For more information: http://www.arminvestorday.com | ||
| Additional link: http://www.alliancerm.org | ||
| Tags: 3d printing, bio technology, 3d bio printing |
| |
| Company Details: | |
| Contact: | Mike Renard | ||
| E-mail: | |||
| Company: | Organovo View Company Profile | ||
| Address: | work6275 Nancy Ridge Dr | ||
| Location: | workSan Diego, CA 92121 United States | ||
| Phone: | workpref(858) 550-9994 | ||
| Web Site: | http://www.organovo.com/ | ||
| |
